Interleukin-4 enhances the in vitro precursor cell recruitment for tumor-specific T lymphocytes in patients with glioblastoma

被引:9
作者
Faber, C
Terao, E
Morga, E
Heuschling, P
机构
[1] Ctr Rech Publ Sanite, L-1150 Luxembourg, Luxembourg
[2] Univ Catholique Louvain, Biol Cellulaire Lab, B-1348 Louvain, Belgium
来源
JOURNAL OF IMMUNOTHERAPY | 2000年 / 23卷 / 01期
关键词
precursor T cell; glioblastoma; interleukin-2; interleukin-4; limiting dilution;
D O I
10.1097/00002371-200001000-00003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Previously the authors showed that interleukin-4 (IL-4), used in combination with IL-2, increases the reduced proliferation rate of T cells of glioblastomabearing patients after in vitro autologous immunization. In this report, they sought to determine whether this effect is caused by a direct mitogenic effect of IL-4, or rather by an indirect effect through an increased expression of the IL-2 receptor subunits or an enhanced recruitment of responsive cells. Flow cytometric analysis confined that the IL-2 receptor subunits are less expressed on circulating T cells from patients with glioblastoma than on those from healthy donors. Because no significant modification of the expression of the p55 and p75 subunits of the IL-2 receptor is observed in cultures treated with both IL-2 and IL-4, the reported enhanced proliferation rate cannot be attributed to an increased level of IL-2 receptor expression. Limiting dilution assays, using autologous target cell immunization, show that treatment with both cytokines (IL-2 plus IL-4) significantly increases the number of recruitable precursor cells without affecting their proliferation rate. These results indicate that IL-4 facilitates an immune response against the autologous tumor cells in glioblastoma-bearing patients by increasing the recruitable precursor T-cell frequency.
引用
收藏
页码:11 / 16
页数:6
相关论文
共 27 条
  • [1] A selective impairment of the IL-2 system in lymphocytes of patients with glioblastomas: Increased level of soluble IL-2R and reduced protein tyrosine phosphorylation
    Ashkenazi, E
    Deutsch, M
    Tirosh, R
    Weinreb, A
    Tsukerman, A
    Brodie, C
    [J]. NEUROIMMUNOMODULATION, 1997, 4 (01) : 49 - 56
  • [2] AUSIELLO CM, 1991, EUR J CANCER, V27, P646, DOI 10.1016/0277-5379(91)90235-6
  • [3] CASEY LS, 1992, J IMMUNOL, V148, P3418
  • [4] PRECURSOR FREQUENCY-ANALYSIS OF HUMAN CYTOLYTIC T LYMPHOCYTES DIRECTED AGAINST AUTOLOGOUS MELANOMA-CELLS
    COULIE, PG
    SOMVILLE, M
    LEHMANN, F
    HAINAUT, P
    BRASSEUR, F
    DEVOS, R
    BOON, T
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1992, 50 (02) : 289 - 297
  • [5] ACTIVATION OF IMMUNOREGULATORY LYMPHOCYTES OBTAINED FROM PATIENTS WITH MALIGNANT GLIOMAS
    ELLIOTT, LH
    BROOKS, WH
    ROSZMAN, TL
    [J]. JOURNAL OF NEUROSURGERY, 1987, 67 (02) : 231 - 236
  • [6] INABILITY OF MITOGEN-ACTIVATED LYMPHOCYTES OBTAINED FROM PATIENTS WITH MALIGNANT PRIMARY INTRACRANIAL TUMORS TO EXPRESS HIGH-AFFINITY INTERLEUKIN-2 RECEPTORS
    ELLIOTT, LH
    BROOKS, WH
    ROSZMAN, TL
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1990, 86 (01) : 80 - 86
  • [7] ELLIOTT LH, 1992, J NEURO-ONCOL, V14, P1
  • [8] INTERLEUKIN-4 AFFECTS PHENOTYPE AND PROLIFERATIVE RESPONSE OF PERIPHERAL-BLOOD LYMPHOCYTES FROM GLIOBLASTOMA PATIENTS AFTER SPECIFIC OR NONSPECIFIC IN-VITRO STIMULATION
    FABER, C
    SANDT, G
    DANG, PT
    MATGE, G
    SCHILTZ, F
    HEUSCHLING, P
    [J]. JOURNAL OF IMMUNOTHERAPY, 1994, 15 (02): : 113 - 118
  • [9] FONTANA A, 1982, J IMMUNOL, V129, P2413
  • [10] JINGWU Z, 1992, Annals of Neurology, V32, P330, DOI 10.1002/ana.410320305